Business Context and Reporting Period
This Form 8-K, dated May 27, 2008, reports a material definitive agreement entered into by Sonus Pharmaceuticals, Inc. (Sonus) with OncoGenex Technologies Inc. (OncoGenex). The filing details a proposed business combination under which Sonus will acquire all outstanding shares of OncoGenex, making it a wholly-owned subsidiary.
Key Financial Metrics and Transaction Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for either company. The transaction structure is defined by the following terms:
- Share Issuance: Sonus will issue 37,062,049 shares of common stock to OncoGenex securityholders, equal to the number of Sonus shares outstanding prior to closing.
- Ownership Split: Upon consummation, existing Sonus stockholders and OncoGenex securityholders will each own 50% of the outstanding Sonus common stock.
- Milestone Shares: Former OncoGenex holders are entitled to up to 25,000,000 additional shares upon achieving specific milestones. These shares will be held in escrow and returned to Sonus for cancellation if not earned within six years.
- Termination Fee: Sonus may be required to pay OncoGenex a termination fee of $500,000 plus out-of-pocket expenses up to $350,000 under certain termination scenarios.
Material Changes and Corporate Actions
Subject to stockholder approval and other closing conditions, the following corporate actions are contemplated concurrently with the closing:
- Reverse Stock Split: Sonus will effect a reverse stock split of its outstanding common stock by a ratio between 1-for-10 and 1-for-20.
- Capital Adjustment: Authorized share capital will be adjusted to approximately two times the number of shares outstanding post-closing (including escrowed Milestone Shares).
- Name Change: The corporation will change its name from "Sonus Pharmaceuticals, Inc." to "OncoGenex Pharmaceuticals, Inc."
- Option Assumption: Existing OncoGenex options will be assumed by Sonus and converted to Sonus common stock options.
Conditions and Voting Agreements
The Arrangement is subject to several conditions, including approval by securityholders of both companies, a final order from the Supreme Court of British Columbia, and an exemption from U.S. securities registration requirements. Directors and certain officers of both companies have executed Voting Agreements to vote in favor of the transaction. These agreements terminate on August 31, 2008, or September 30, 2008, depending on SEC review status.
Amendment to Rights Agreement
Sonus entered into a Third Amendment to its Amended and Restated Rights Agreement to ensure that OncoGenex and its affiliates are not deemed an "Acquiring Person" and that no triggering events occur solely as a result of the Arrangement.
Investor Verification Checklist
- Verify the final terms of the Reverse Stock Split ratio (between 1-for-10 and 1-for-20) once approved by stockholders.
- Review the upcoming proxy statement for detailed financial data on OncoGenex and the specific milestones required to earn the 25,000,000 Milestone Shares.
- Confirm the status of regulatory approvals, specifically the order from the Supreme Court of British Columbia and the Section 3(a)(10) exemption.
- Monitor the Voting Agreements expiration dates (August 31 or September 30, 2008) to assess the timeline for stockholder approval.
- Check for any updates regarding the potential $500,000 termination fee liability if the deal is terminated.